These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22077794)

  • 1. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 6. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 7. [Contribution of a new nitrosourea compound: fotemustine].
    Boaziz C
    Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
    Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New toxicity of fotemustine: diffuse interstitial lung disease].
    Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
    Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
    Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
    Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
    Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
    Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P; Dreno B; Bureau B; Litoux P
    Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
    Addeo R; Zappavigna S; Luce A; Facchini S; Caraglia M
    Expert Opin Drug Saf; 2013 Sep; 12(5):729-40. PubMed ID: 23560594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
    Tas F; Camlica H; Topuz E
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic uveal melanoma with intravenous fotemustine.
    Spagnolo F; Grosso M; Picasso V; Tornari E; Pesce M; Queirolo P
    Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
    Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
    Terheyden P; Becker JC; Kämpgen E; Bröcker EB
    Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.